Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 215

Sort by

Sort Order Select

Journal Articles

Zanubrutinib + obinutuzumab + sonrotoclax in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL): Initial results from an ongoing phase 1/1b study, BGB-11417-101

Jacob Soumerai, Stephen Opat, Chan Cheah, Mazyar Shadman, Emma Verner, Monica Tani, Marc Hoffmann, Lori Leslie, Shuo Ma, Yiqian Fang, Gabriel Man, Binghao Wu, Charity Henrich, Sheel Patel, Remus Vezan, Constantine Tam

Blood (2025) 146 (Supplement 1): 3890.

https://doi.org/10.1182/blood-2025-3890

Published: 2025

Journal Articles

Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience

Blood (2025) 146 (Supplement 1): 3885.

https://doi.org/10.1182/blood-2025-3885

Published: 2025

Journal Articles

Evaluation of CAR-T access barriers in Washington and Alaska: A single-center experience prior to implementing program capacity expansion

Melinda Biernacki, Agie Cole, Kausar Abukar, Isatou Barrow, Lorenzo Iovino, Natalie Wuliji, Mohamed Sorror, Erik Kimble, Edus Warren, Ryan Cassaday, Jordan Gauthier, Meredith Durbin, Alexandre Hirayama, Brian Till, Aude Chapuis, Filippo Milano, Lawrence Fong, Mazyar Shadman, Folashade Otegbeye

Blood (2025) 146 (Supplement 1): 6202.

https://doi.org/10.1182/blood-2025-6202

Published: 2025

Journal Articles

Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis

Ryan Lynch, Christina Poh, Mazyar Shadman, Brian Till, Mengyang Di, Chaitra Ujjani, Vikram Raghunathan, Stephen Smith, David Maloney, Daria Gausman, Heather Rasmussen, David Russler-Germain, Todd Fehniger, David Kurtz, Ash Alizadeh, Jenna Voutsinas, Ajay Gopal

Blood (2025) 146 (Supplement 1): 3591.

https://doi.org/10.1182/blood-2025-3591

Published: 2025

Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study

Constantine Tam, Chan Cheah, John Seymour, Ricardo Parrondo, Mazyar Shadman, Damien Roos Weil, Stephan Stilgenbauer, Barbara Eichhorst, Herbert Eradat, Steven Treon, Yanan Zhang, Linlin Xu, Kunthel By, Shannon Fabre, Motohisa Takai, Amit Agarwal, Annamaria Frustaci

Blood (2025) 146 (Supplement 1): 3583.

https://doi.org/10.1182/blood-2025-3583

Published: 2025

Journal Articles

MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naive CLL: Initial results from an ongoing phase 1/1b study, BGB-11417-101

Marc Hoffmann, Shuo Ma, Herbert Eradat, Constantine Tam, Masa Lasica, Paul Hampel, Emma Verner, Lori Leslie, Christopher D'Angelo, Jacob Soumerai, Mazyar Shadman, Chan Cheah, Monica Tani, Yiqian Fang, Binghao Wu, Gabriel Man, Sheel Patel, Remus Vezan, Stephen Opat

Blood (2025) 146 (Supplement 1): 793.

https://doi.org/10.1182/blood-2025-793

Published: 2025

Journal Articles

Outcomes of autologous transplant (ASCT) in patients with chemosensitive late relapse of large B-cell lymphoma (LBCL)

Lorenzo Iovino, Ningxin Ma, Mohamed Kharfan-Dabaja, Alex Herrera, Craig Sauter, Mehdi Hamadani, Peter Riedell, Ajay Gopal, Leona Holmberg, Qian Wu, Sonali Smith, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 5483.

https://doi.org/10.1182/blood-2025-5483

Published: 2025

Journal Articles

Sonic: Escalated inpatient ramp-up of sonrotoclax in CLL/SLL and MCL

Jennifer Huang, Laura Samples, Ted Gooley, Margo Fredericks, Stephanie Louie, Grace Bishop, Christine Crider, Mehrdad Azar, Neena Kennedy, Mengyang Di, Stephen Smith, Brian Till, Ajay Gopal, Ryan Lynch, Chaitra Ujjani, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 2136.

https://doi.org/10.1182/blood-2025-2136

Published: 2025

Journal Articles

Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment (tx)-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) and continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study

Constantine Tam, Talha Munir, Tadeusz Robak, Jennifer Brown, Brad Kahl, Paolo Ghia, Stephen Opat, Patricia Walker, Masa Lasica, Ian Flinn, Jiayi Shen, Nataliya Kuptsova-Clarkson, Marcus Lefebure, Jamie Hirata, Wojciech Jurczak, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 2129.

https://doi.org/10.1182/blood-2025-2129

Published: 2025

Journal Articles

Venetoclax retreatment of real-world patients with chronic lymphocytic leukemia previously treated with venetoclax-based regimens

Mazyar Shadman, Meghan Thompson, Nilanjan Ghosh, Nnadozie Emechebe, Beenish Manzoor, Godwin Okoye, Neto Coulibaly, Wendy Sinai, Sophia Li, Rajesh Kamalakar, Brian Hill

Blood (2025) 146 (Supplement 1): 2108.

https://doi.org/10.1182/blood-2025-2108

Published: 2025

Journal Articles

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

Blood (2025) 146 (Supplement 1): 928.

https://doi.org/10.1182/blood-2025-928

Published: 2025

Journal Articles

Long term safety and long term disease control of oral ixazomib and short-course rituximab in untreated iNHL

Xiancheng Wu, Solomon Graf, Ryan Lynch, Chaitra Ujjani, Ted Gooley, Jenna Voutsinas, Heather Rasmussen, Wendy Felder, Kristi Matsumura, Andrew Cowan, Stephen Smith, Mazyar Shadman, Edus Warren, Jonathan Fromm, Ajay Gopal

Blood (2025) 146 (Supplement 1): 5355.

https://doi.org/10.1182/blood-2025-5355

Published: 2025

Journal Articles

Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study

Blood (2025) 146 (Supplement 1): 5352.

https://doi.org/10.1182/blood-2025-5352

Published: 2025

Journal Articles

Symptom-based progression-free survival (S-PFS) as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Results from the ALPINE trial

Jennifer Brown, Timothy Victor, Alan Wu, Nicole Lamanna, Constantine Tam, Lugui Qiu, Rasika Korde, Tommi Salmi, Gisoo Barnes, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 711.

https://doi.org/10.1182/blood-2025-711

Published: 2025

Journal Articles

INSIGHT: A baseline laboratory profile independently predicts outcomes and demonstrates superiority of lisocabtagene maraleucel (liso-cel) over standard of care (SOC) in second-line (2L) large B-cell lymphoma (LBCL) regardless of baseline profile

Sahar Ansari, Manali Kamdar, Eniko Papp, Mazyar Shadman, Jeremy Abramson, Begüm D. Topçuoglu, Pei Yang, Lara Stepan, Pradipta Ray, Amanda Przespolewski, Krishna R. Juluri, Eric Bleickardt, Debasmita Roy, Alessandro Crotta, Timothy B. Campbell, Julie A. Rytlewski, Abood Okal, Ethan Thompson, Leanne Peiser

Blood (2025) 146 (Supplement 1): 1775.

https://doi.org/10.1182/blood-2025-1775

Published: 2025

Journal Articles

Causes of death in chronic lymphocytic leukemia/small lymphocytic lymphoma during the novel agent era: A population-based analysis

Mengyang Di, Scott Huntington, Jenna Voutsinas, Qian Wu, Scott Ramsey, Jennifer Huang, Ajay Gopal, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 4520.

https://doi.org/10.1182/blood-2025-4520

Published: 2025

Journal Articles

Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b/2 EPCORE CLL-1 trial

Arnon Kater, Ann Janssens, Herbert Eradat, Fritz Offner, Jose D. Sandoval-Sus, Mazyar Shadman, Christian Poulsen, Jacob Christensen, Meghan Thompson, Meijian Guan, Andrew J. Steele, Marcia Rios, Marie Holst Mørch, Toshihiko Oki, Rebecca Valentin, Mar Bellido, Barbara Eichhorst

Blood (2025) 146 (Supplement 1): 1017.

https://doi.org/10.1182/blood-2025-1017

Published: 2025

Journal Articles

Promote-FL: Pirtobrutinib and mosunetuzumab to enhance treatment efficacy for patients with relapsed/refractory follicular lymphoma

Mengyang Di, Qian Wu, Ryan Lynch, Stephen Smith, Mazyar Shadman, Paul Martin, Brian Till, Neena Kennedy, Chaitra Ujjani, Ajay Gopal

Blood (2025) 146 (Supplement 1): 5394.

https://doi.org/10.1182/blood-2025-5394

Published: 2025

Journal Articles

CAR T cell therapy referral patterns and characteristics of patients with relapsed or refractory (R/R) large B cell lymphoma (LBCL) in the United States

Mazyar Shadman, Fei Fei Liu, Christine Fu, Michael Cantrell, Amit Goyal, Dwaipayan Mukherjee, Tara Graff

Blood (2025) 146 (Supplement 1): 6272.

https://doi.org/10.1182/blood-2025-6272

Published: 2025

Journal Articles

Outcomes of CAR T-cell therapies after prior treatment with fixed-duration mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Adam Braun, Nancy Bartlett, Dai Chihara, Loretta Nastoupil, Mazyar Shadman, Dimitrios Tzachanis, Hunter Cochran, Jennifer Huang, Mei Wu, Michael C. Wei, Shen Yin, Jing Qi Hao, Qian Zhu, Yong Mun, Elizabeth Budde

Blood (2025) 146 (Supplement 1): 6261.

https://doi.org/10.1182/blood-2025-6261

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Zanubrutinib + obinutuzumab + sonrotoclax in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL): Initial results from an ongoing phase 1/1b study, BGB-11417-101

Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience

Evaluation of CAR-T access barriers in Washington and Alaska: A single-center experience prior to implementing program capacity expansion

Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study

MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naive CLL: Initial results from an ongoing phase 1/1b study, BGB-11417-101

Outcomes of autologous transplant (ASCT) in patients with chemosensitive late relapse of large B-cell lymphoma (LBCL)

Sonic: Escalated inpatient ramp-up of sonrotoclax in CLL/SLL and MCL

Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment (tx)-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) and continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study

Venetoclax retreatment of real-world patients with chronic lymphocytic leukemia previously treated with venetoclax-based regimens

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

Long term safety and long term disease control of oral ixazomib and short-course rituximab in untreated iNHL

Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study

Symptom-based progression-free survival (S-PFS) as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Results from the ALPINE trial

INSIGHT: A baseline laboratory profile independently predicts outcomes and demonstrates superiority of lisocabtagene maraleucel (liso-cel) over standard of care (SOC) in second-line (2L) large B-cell lymphoma (LBCL) regardless of baseline profile

Causes of death in chronic lymphocytic leukemia/small lymphocytic lymphoma during the novel agent era: A population-based analysis

Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b/2 EPCORE CLL-1 trial

Promote-FL: Pirtobrutinib and mosunetuzumab to enhance treatment efficacy for patients with relapsed/refractory follicular lymphoma

CAR T cell therapy referral patterns and characteristics of patients with relapsed or refractory (R/R) large B cell lymphoma (LBCL) in the United States

Outcomes of CAR T-cell therapies after prior treatment with fixed-duration mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only